An early intranasal bremelanotide pilot study examined subjective and physiological sexual-response measures in a small group of premenopausal women. Separately, an intranasal oxytocin crossover trial in women with sexual dysfunction found no significant treatment advantage over placebo despite changes during both periods.
Those studies involved the ingredients separately, not this compounded combination. They also studied specific populations and endpoints. The honest conclusion is that both pathways have been researched, the blend has limited direct human evidence, and a provider should not treat the pairing as a guaranteed or stronger version of either ingredient alone.
Route matters as well. Bremelanotide has been studied in both intranasal and injectable development programs, while the approved product uses an injectable route. Oxytocin has its own device and absorption questions when administered intranasally. Putting both into one nasal bottle creates formulation, exposure and tolerability questions that separate ingredient studies cannot answer.
A combination can also make attribution harder. If someone reports nausea, flushing, headache, a cardiovascular change or an unexpected emotional response, the experience does not identify which ingredient contributed. That is a reason for more conservative follow-up and for considering whether a single-ingredient discussion would be clearer.
